$INBX

4 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

—

Win rate (3m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 1m ago

$INBXSEC Form 4bullish

Lappe Mark · Chief Executive Officer at Inhibrx Biosciences, Inc. · 19d ago1 prior · awaiting results

Long 10,040 shares of INBX

Bought 10,040 @ $84.56 avg · $848,977 · 2026-10-14

Form 4: Lappe Mark bought INBX

Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 10,040 shares of INBX at an average $84.56, roughly $848,977, in a Form 4 filed 2026-10-14.

At post $85.26Now $72.24-15.3% since posted1m ago

1d+6.1%

3d+5.4%

1w+15.2%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$INBXSEC Form 4bullish

Kayyem Jon Faiz · Inhibrx Biosciences, Inc. · 46d agono track record yet

Long 5,000 shares of INBX

Bought 5,000 @ $100.00 avg · $500,000 · 2026-09-16

Form 4: Kayyem Jon Faiz bought INBX

Kayyem Jon Faiz (Director at Inhibrx Biosciences, Inc.) reported an open-market purchase of 5,000 shares of INBX at an average $100.00, roughly $500,000, in a Form 4 filed 2026-09-17.

At post $104.73Now $72.24-31.0% since posted1m ago

1d+4.4%

3d+4.4%

1w-4.1%

1m-14.2%

3m—

6m—

1y—

View filing on SEC.gov →

$INBXSEC Form 4bullish

FORSYTH DOUGLAS · Inhibrx Biosciences, Inc. · 55d agono track record yet

Long 2,500 shares of INBX

Bought 2,500 @ $114.65 avg · $286,617 · 2026-09-08

Form 4: FORSYTH DOUGLAS bought INBX

FORSYTH DOUGLAS (Director at Inhibrx Biosciences, Inc.) reported an open-market purchase of 2,500 shares of INBX at an average $114.65, roughly $286,617, in a Form 4 filed 2026-09-08.

At post $114.34Now $72.24-36.8% since posted1m ago

1d-1.3%

3d-4.4%

1w-7.6%

1m-18.9%

3m—

6m—

1y—

View filing on SEC.gov →

$INBXSEC Form 4bullish

Lappe Mark · Chief Executive Officer at Inhibrx Biosciences, Inc. · 55d ago1 prior · awaiting results

Long 25,000 shares of INBX

Bought 25,000 @ $105.82 avg · $2,645,399 · 2026-09-08

Form 4: Lappe Mark bought INBX

Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 25,000 shares of INBX at an average $105.82, roughly $2,645,399, in a Form 4 filed 2026-09-08.

At post $114.34Now $72.24-36.8% since posted1m ago

1d-1.3%

3d-4.4%

1w-7.6%

1m-18.9%

3m—

6m—

1y—

View filing on SEC.gov →

End of results.